Beside predictive glioma biomarkers in clinical use, such as 6-O-methylguanine-DNA methyltransferase (MGMT) promoter methylation and 1p/19q codeletion, further novel predictive biomarkers emerge for guiding the post-surgery treatment of patients, e.g., BRAF and IDH mutations, EGFR amplification and vIII variant expression, FGFR-TACC fusion. The gene discussed is IDH2; the disease is glioma.